Patient and Public Involvement and Engagement in Research With Children and Young People With Sickle Cell Disorder and Their Families
Patient and Public Involvement and Engagement in Research on Life-limiting Conditions With Children and Young People With Sickle Cell Disorder and Their Families
Aim: To co-produce resources for inclusive and equitable Patient and Public Involvement and Engagement in research on life-limiting conditions, with children and young people with sickle cell disorder and their families.
Methods: Workshops with a) members of a patient advocacy organisation (Sickle Cell Society n=5) b): i) Children and young people (10-18 years) with sickle cell disorder (n=15) and ii) their siblings (10-18 years, n=10) and iii) their parents (n=15), c) Researchers form the Cicely Saunders Institute Outputs: Resources that enable children and young people with sickle cell disorder and their families to engage in research
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Aim:
To co-produce resources for inclusive and equitable Patient and Public Involvement and Engagement in research on life-limiting conditions, with children and young people with sickle cell disorder and their families.
Objectives:
- Partner and collaborate with the Sickle Cell Society to continue to build on the work of the Cicely Saunders Institute to support a thriving Patient and Public Involvement and Engagement community that includes children and young people and their families
- Listen, hear, and understand what is important for children and young people with sickle cell disorder and provide them with the knowledge and skills to collaborate with researchers at the Cicely Saunders Institute during the design and implementation, analysis, and publication of research
- Equip staff within the Cicely Saunders Institute with the knowledge, understanding and awareness of the role children and young people with sickle cell disorder and their families can play in patient-involved research to ensure pathways for prioritizing and disseminating patient led research are realised
- Use data from objectives 1-3 to co-produce resources that may be used with a broader population of children and young people with serious and life-limiting conditions and their families to enable them to become equal partners in research
- Use learning from the proposed project with the Sickle Cell Society as an exemplar partnership, to inform future Patient and Public Involvement and Engagement with children and young people with other serious and life-limiting conditions including cancer and neuro-disabilities as the investigators expand the research remit at the Cicely Saunders Institute.
Background:
Public involvement must be diverse and inclusive to enable research that has the potential to reach those that stand to benefit from it the most, and thus to address issues of health equity and accessibility. Yet, long-standing evidence has shown that those most likely to be involved in research come from a narrow section of the population, from older age groups, white ethnic and higher socio-economic backgrounds. It is widely recognised that many groups are underserved and underrepresented in research.
Underserved groups include children, young people and adults from different minority ethnic groups, socio-economically disadvantaged groups, migrants, asylum seekers, people with mental health conditions and multiple health conditions. Children and young people, as a group have few opportunities for research involvement. There is also limited evidence on optimal models for partnerships in research.
Changing the balance of power and promoting wider participation, empowerment, diversity, and equality, are seen as neglected aspects of involvement that, if given due attention, can offer a way to move beyond involvement at the lowest levels of consultation to partnering and collaborating with a wider diversity of people and communities.
Methods:
Design: A sequential design involving three work packages
• WP1 will address Objectives 1 and 2: Apr-June 2023
The investigators will hold separate child and adult online/face to face scoping workshops (n=3) with:
Group B(i) children and young people with sickle cell disorder (n=15) and B(ii) their siblings (n=10) and B(iii) their parents (n=15) recruited via charity partners to:
(i) Explain what research is, how it is conducted, relevant policies and the mission statement of the Cicely Saunders Institute (ii) Review structures and processes for equitable and inclusive Patient and Public Involvement and Engagement for children and young people with sickle cell disorder and their families (iii) Identify relevant and appropriate training/education/skills needed to enable children and young people with sickle cell disorder and their families to engage in research.
The child and young people's workshop will be facilitated by an artist to assist with activities to engage participants. These workshops will be evaluated by those involved using surveys which will be administered at the end of the workshops.
- WP2 will address objective 3: Jul-Aug 2023 The investigators will hold online/face to face workshops (n=2) with researchers from the Cicely Saunders Institute (n=10) and members of Group B (n=10-15) to enable them to work together to identify resources needed for meaningful Patient and Public Involvement and Engagement with children and young people with sickle cell disorder and their families to take forward into WP3. These workshops will also be evaluated by those involved using surveys which will be administered at the end of the workshops.
- WP3 will address objectives 4 and 5: Sept-Dec 2023 Through a combination of online/face to face working groups (n=2), the investigators will work with children and young people with sickle cell disorder and their families (n=10-15 at each workshop) as well as researchers from the Cicely Saunders Institute (n=5) to co-produce resources that enable them to engage meaningfully in research incorporating the skills and knowledge identified in WP1. One of these workshops will be facilitated by an artist to help children develop their ideas into future resources for meaningful Patient and Public Involvement and Engagement. This will facilitate their involvement in future funding applications that are driven by them.
The investigators will have a final celebratory event with Group A: Sickle Cell Society and Groups B(i) children and young people with sickle cell disorder (n=15), Bii) their siblings (n=10) and Biii) their parents (n=15) to showcase achievements and plan next steps. The celebratory event will include an evaluation of the whole project.
Outputs:
WP1: (i) Partnership with a charity organisation, the Sickle Cell Society (ii) guidance on reaching minority ethnic groups and publicizing research opportunities; (iii) training skills analysis to enable children and young people with sickle cell disorder and their families to engage in research in a meaningful way.
WP2: Identification of resources needed to facilitate meaningful involvement of children and young people with sickle cell disorder and their families to engage in research WP3: (i) Resources that enable children and young people with sickle cell disorder and their families to engage in research (ii) a future strategy for meaningful Public Involvement and Engagement with children and young people with sickle cell disorder and their families (iii) an exemplar to inform future Patient and Public Involvement and Engagement with children and young people with other serious and life-limiting conditions including cancer and neuro-disabilities as the investigators expand the research remit.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE5 9RS
- King's College London
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
- Group A: Members of a patient advocacy organisation (Sickle Cell Society n=5)
Group B:
i) Children and young people (10-18 years) with sickle cell disorder (n=15) ii) their siblings (10-18 years, n=10) iii) their parents (n=15)
- Group C: Researchers working with children with life-limiting or life changing conditions
Description
Inclusion Criteria:
- Group A: Members of a patient advocacy organisation (Sickle Cell Society n=5)
Group B:
i) Children and young people (10-18 years) with sickle cell disorder (n=15) ii) their siblings (10-18 years, n=10) iii) their parents (n=15)
- Group C: Researchers working with children with life-limiting or life changing conditions
Exclusion Criteria:
- Group A: Members of patient advocacy organisations other than the Sickle Cell Society
Group B:
i) Children and young people younger than ten years or older than 18 years and those without sickle cell disorder (n=15) ii) siblings younger than ten years or older than 18 years and without a brother or sister with sickle cell disorder iii) parents of children with conditions other than sickle cell disorder
- Group C: Researchers who do not have experience working with children with life-limiting or life changing conditions
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Participants with personal experience of sickle cell disorder.
Participants with personal experience of sickle cell disorder (parents, affected children or siblings).
|
|
Researchers
Researchers working with children with life limiting or life changing conditions
|
|
Members of a patient advocacy organisation
Members of a patient advocacy organisation (Sickle Cell Society)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Workshops with participants to develop resources that enable children and young people with sickle cell disorder and their families to engage in research
Time Frame: 8 months
|
Resources that enable children and young people with sickle cell disorder and their families to engage in research
|
8 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SCD Support
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
NCT04579926CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC Disease
-
NCT07540767Not yet recruitingSickle Cell Disease | Sickle Cell Disease (SCD) | Sickle Cell Anemia in Children | Sickle Cell | Sickle Cell Anemia (HbSS)
-
NCT03763656CompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, Thalassemia
-
NCT01925001WithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C Disease
-
NCT06396403CompletedSickle Cell Disease | Sickle Cell SC Disease | Sickle Cell-SS Disease | Sickle Cell Retinopathy
-
NCT01356485CompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C Disease
-
NCT05506358CompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS Disease
-
NCT01350232TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemia
-
NCT04201210RecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin S
-
NCT03971136RecruitingSickle-Cell Disease Nos With Crisis